About Luiz Fernando dos Reis Falcao
Clinical Trials at Luiz Fernando dos Reis Falcao
During the past decade, Luiz Fernando dos Reis Falcao conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Luiz Fernando dos Reis Falcao
According to Clinical.Site data, the most researched conditions in "Luiz Fernando dos Reis Falcao" are
"Anesthesia" (2 trials). Many other conditions were trialed in "Luiz Fernando dos Reis Falcao" in a lesser frequency.
Clinical Trials Intervention Types at Luiz Fernando dos Reis Falcao
Most popular intervention types in "Luiz Fernando dos Reis Falcao" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Clonidine" (1 trials), "Placebo" (1 trials) and "bupivacaine 0.5%" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Luiz Fernando dos Reis Falcao
The vast majority of trials in "Luiz Fernando dos Reis Falcao" are
2 trials for "All" genders.
Clinical Trials Status at Luiz Fernando dos Reis Falcao
Currently, there are NaN active trials in "Luiz Fernando dos Reis Falcao".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in Luiz Fernando dos Reis Falcao,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Luiz Fernando dos Reis Falcao, 0 "Phase 1"
clinical trials were conducted, 2 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".